scholarly journals Non steroidal anti-inflammatory drugs in the prevention of cystoid macular edema after uneventful cataract surgery

2014 ◽  
pp. 1209 ◽  
Author(s):  
Alejandro Allocco ◽  
Julia Ponce ◽  
Nicolas Quintana ◽  
Mauricio Magurno
Keyword(s):  
Cataract Surgery ◽  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Comparison of the Efficacy and Safety of Non-Steroidal Anti-Inflammatory Drugs and Corticosteroid Drugs for Prevention of Cystoid Macular Edema After Cataract Surgery: A Systematic Review and Network Meta-Analysis

2021 ◽  
Author(s):  
Shanshan Li ◽  
Hui-Hui Wang ◽  
Da-Wei Zhang
Keyword(s):  
Cataract Surgery ◽  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Corticosteroid Drugs

Abstract Introduction: To compare the efficacy and safety of non-steroidal anti-inflammatory drugs (NSAID), corticosteroid (CS), and a combination of both drugs to prevent cystoid macular edema (CME) after cataract surgery. Methods We searched Pubmed, Cochrane Library, and Embase electronic databases to assess the relevant randomized controlled trials (RCTs) up to 28 April 2021. Network meta-analysis was registered on PROSPERO (CRD42020182520). Results Twenty-four RCTs were included in this review. The NSAID and combination of both drugs were significantly reduced the risk of developing CME than CS alone in non-diabetics and mix population. In the ranking profiles, the combination therapy showed a significant advantage over the single drugs and was less likely to develop CME. Diclofenac was the most likely to reduce the odds of developing CME compared with bromfenac and nepafenac. Dexamethasone was the most likely to reduce the odds of developing CME compared with betamethasone and fluorometholone. Conclusion NSAID combination with CS has significantly reduced the risk of developing CME postoperatively than the single drug. Diclofenac was superior to bromfenac and nepafenac in preventing CME. Dexamethasone was superior to betamethasone and fluorometholone in preventing CME.

scholarly journals Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac

2020 ◽  
Vol 9 (9) ◽  
pp. 3034
Author(s):  
Alexander Aaronson ◽  
Asaf Achiron ◽  
Raimo Tuuminen
Keyword(s):  
Visual Acuity ◽  
Cataract Surgery ◽  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Randomized Clinical Trials ◽  
Clinical Course ◽  
Total Incidence ◽  
Corrected Distance Visual Acuity ◽  
Anti Inflammatory ◽  
Clinically Significant

Background: To evaluate the clinical course of pseudophakic cystoid macular edema (PCME) treated with topical non-steroidal anti-inflammatory drugs (NSAIDs). Methods: An analysis of the clinical course of PCME consisting of 536 eyes of 536 patients from five consecutive randomized clinical trials aimed at the optimization of anti-inflammatory medication in patients undergoing routine cataract surgery. PCME was classified as (i) grade 0a; no macular thickening, (ii) grade 0b; macular thickening (central subfield macular thickness (CSMT) increase of at least 10%) without signs of macular edema, (iii) grade I; subclinical PCME, (iv) grade II; acute PCME, (v) grade III; long-standing PCME. Eyes with PCME classification from grade I onwards were treated with nepafenac 1 mg/mL t.i.d. for two months. Results: CSMT increase of at least 10% at any postoperative timepoint with cystoid changes—a criterion for PCME—was found in 19 of 536 eyes (total incidence 3.5%). Of these 19 eyes, 13 eyes (total incidence 2.4%) had clinically significant PCME. PCME was considered clinically significant when both of the following visual acuity criteria were fulfilled. At any timepoint after the cataract surgery both the corrected distance visual acuity (CDVA) gain was less than 0.4 decimals from that of preoperative CDVA, and the absolute CDVA level remained below 0.8 decimals. Only one of the 19 eyes with criteria for PCME (total incidence 0.2%, incidence of PCME eyes 5.3%) showed no macular edema resolution within 2 months after topical nepafenac administration. Conclusions: PCME in most cases is self-limiting using topical nepafenac without any further need for intravitreal treatment.

Sign in / Sign up

Export Citation Format

Share Document